Press Release

Seraxis Inc. closed a Series B financing Round and enters into a collaboration with Medytox Inc.

admin

August 10, 2016

About Seraxis, Inc.

Seraxis is a private biotechnology company launched in 2013 and located in Germantown, Maryland. The Seraxis mission is to develop a practical and potent cell replacement therapy for insulin-dependent diabetes.

Seraxis Inc. closed a Series B financing Round and enters into a collaboration with Medytox Inc.

About Seraxis, Inc.

Cell Therapy Startup, Seraxis, secures Series A Funding.

Seraxis Inc. announces a commercialization grant award from the Maryland Stem Cell Research Fund (MSCRF).

Related articles

Seraxis Presents Successful Results Using Synthetic Replacement Endocrine Clusters for Type 1 Diabetes at the 4th IPITA / HSCI / JDRF Summit.

Seraxis wins grant from Maryland Stem Cell Research Fund to accelerate development of allogenetically compatible pancreatic islet replacement therapy for functional cure of T1D.

Seraxis’ manufacturing suite completes GMP quality system audit ahead of SR-02 IND filing and transplantation of pancreatic clusters to patients with Type 1 Diabetes.